Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Sarcoma 2Lung Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Renal Cell 2Smoldering Multiple Myeloma 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Melanoma 1Kidney Neoplasms 1Glioma 1Breast Neoplasms 1

Interventions

Dexamethasone 338Bortezomib 188Lenalidomide 186Cyclophosphamide 166Melphalan 124Calcium Dobesilate 108daratumumab 95fludarabine phosphate 69carfilzomib 69pomalidomide 68Peripheral Blood Stem Cell Transplantation 64Filgrastim 56Thalidomide 55Busulfan 53Mycophenolic Acid 52Tacrolimus 45Granulocyte Colony-Stimulating Factor 45ixazomib 43fludarabine 42Whole-Body Irradiation 40Cyclosporine 35Etoposide 33dexamethasone acetate 31Antilymphocyte Serum 31isatuximab 29dexamethasone 21-phosphate 26Prednisone 26elotuzumab 25Biopsy 25auricularum 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Multiple Myeloma × AH 111585 × Clear all
NCT01571726 2019-12-16

Imaging Studies and the Development of Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡